JP2014527529A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527529A5
JP2014527529A5 JP2014526090A JP2014526090A JP2014527529A5 JP 2014527529 A5 JP2014527529 A5 JP 2014527529A5 JP 2014526090 A JP2014526090 A JP 2014526090A JP 2014526090 A JP2014526090 A JP 2014526090A JP 2014527529 A5 JP2014527529 A5 JP 2014527529A5
Authority
JP
Japan
Prior art keywords
hydroxy
alkyl
methylsulfonamido
cyclopropyl
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014526090A
Other languages
English (en)
Japanese (ja)
Other versions
JP6367712B2 (ja
JP2014527529A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/050268 external-priority patent/WO2013028371A1/en
Publication of JP2014527529A publication Critical patent/JP2014527529A/ja
Publication of JP2014527529A5 publication Critical patent/JP2014527529A5/ja
Application granted granted Critical
Publication of JP6367712B2 publication Critical patent/JP6367712B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014526090A 2011-08-19 2012-08-10 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物 Expired - Fee Related JP6367712B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US61/525,440 2011-08-19
US201261650681P 2012-05-23 2012-05-23
US61/650,681 2012-05-23
PCT/US2012/050268 WO2013028371A1 (en) 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016249387A Division JP2017125010A (ja) 2011-08-19 2016-12-22 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物

Publications (3)

Publication Number Publication Date
JP2014527529A JP2014527529A (ja) 2014-10-16
JP2014527529A5 true JP2014527529A5 (https=) 2015-09-17
JP6367712B2 JP6367712B2 (ja) 2018-08-01

Family

ID=47746761

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014526090A Expired - Fee Related JP6367712B2 (ja) 2011-08-19 2012-08-10 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物
JP2016249387A Pending JP2017125010A (ja) 2011-08-19 2016-12-22 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016249387A Pending JP2017125010A (ja) 2011-08-19 2016-12-22 C型肝炎ウイルス感染の治療のためのベンゾフラン化合物

Country Status (38)

Country Link
US (2) US8927593B2 (https=)
EP (2) EP2744332B1 (https=)
JP (2) JP6367712B2 (https=)
KR (1) KR101913800B1 (https=)
CN (1) CN103732065B (https=)
AR (1) AR087563A1 (https=)
AU (1) AU2012299295B2 (https=)
BR (1) BR112014002845A2 (https=)
CA (1) CA2844086A1 (https=)
CL (2) CL2014000393A1 (https=)
CO (1) CO6862153A2 (https=)
CR (1) CR20140078A (https=)
CY (1) CY1118399T1 (https=)
DK (1) DK2744332T3 (https=)
DO (1) DOP2014000034A (https=)
EA (1) EA032841B1 (https=)
ES (1) ES2611731T3 (https=)
HR (1) HRP20161743T1 (https=)
HU (1) HUE030300T2 (https=)
IL (1) IL230487B (https=)
IN (1) IN2014CN00572A (https=)
JO (1) JO3281B1 (https=)
LT (1) LT2744332T (https=)
MA (1) MA35443B1 (https=)
ME (1) ME02588B (https=)
MX (1) MX354676B (https=)
PE (1) PE20141201A1 (https=)
PH (1) PH12014500385A1 (https=)
PL (1) PL2744332T3 (https=)
PT (1) PT2744332T (https=)
RS (1) RS55462B1 (https=)
SG (1) SG10201606883QA (https=)
SI (1) SI2744332T1 (https=)
SM (2) SMT201700028T1 (https=)
TW (1) TWI538915B (https=)
UY (1) UY34274A (https=)
WO (1) WO2013028371A1 (https=)
ZA (1) ZA201401020B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003556A2 (pt) * 2011-08-17 2017-03-21 Glaxosmithkline Llc método de tratamento de vírus, e, composição farmacêutica
PT2744332T (pt) 2011-08-19 2017-01-24 Glaxo Group Ltd Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c
US20170312297A1 (en) * 2014-11-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long Acting Pharmaceutical Compositions For Hepatitis C
PE20170922A1 (es) * 2014-11-10 2017-07-12 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones de accion prolongada de combinacion y procedimientos para hepatitis c
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
US11738088B2 (en) 2016-08-01 2023-08-29 University of Pittsburgh—of the Commonwealth System of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
SG11201908012SA (en) * 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
IL276013B2 (en) * 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd Pi4kiiibeta inhibitors
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co., Ltd. NEW SUBSTITUTED CONDENSED RING CONNECTION
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统
CN117242080A (zh) * 2020-12-18 2023-12-15 勃林格殷格翰动物保健美国公司 含硼吡唑化合物、包括其的组合物、其方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
WO2001002424A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
JP4162491B2 (ja) 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
CN1731993A (zh) * 2002-11-01 2006-02-08 维洛药品公司 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法
BRPI0619132A2 (pt) * 2005-12-01 2011-09-13 Wyeth Corp composto métodos para inibir a replicação de um vìrus de hepatite c, para tratar ou prevenir uma infecção viral de hepatite c em um mamìfero e para inibir rna polimerase dependente do rna de hepatite c, e, composição farmacêutica
ME02188B (me) 2006-02-16 2016-02-20 Anacor Pharmaceuticals Inc Mali molekuli koji sadrže boron kao antiinflamatorni agensi
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
EP2520561B1 (en) * 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
EP2245023B1 (en) * 2008-02-14 2011-12-28 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201008933A (en) 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
AR080185A1 (es) 2010-02-19 2012-03-21 Glaxo Group Ltd Derivados de acido boronico y benzofurano, composiciones farmaceuticas que los contienen,y uso de los mismos en el tratamiento y/o prevencion de infecciones virales, en particular por el virus de hepatitis c(hcv).
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
AR080433A1 (es) 2010-03-02 2012-04-11 Merck Sharp & Dohme Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen.
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
BR112014003556A2 (pt) * 2011-08-17 2017-03-21 Glaxosmithkline Llc método de tratamento de vírus, e, composição farmacêutica
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
PT2744332T (pt) 2011-08-19 2017-01-24 Glaxo Group Ltd Compostos de benzofurano para o tratamento de infeções por vírus de hepatite c

Similar Documents

Publication Publication Date Title
JP2014527529A5 (https=)
JP2016538313A5 (https=)
JP2014530900A5 (https=)
RU2485131C2 (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства
JP2017537949A5 (https=)
JP2013535487A5 (https=)
RU2015151502A (ru) Химические соединения
JP2012505836A5 (https=)
JP2016525102A5 (https=)
JP2011502958A5 (https=)
RU2011144763A (ru) 6-(3-азабицикло[3.1.0]гекс-3-ил)-2-фенилпиримидины
JP2013508279A5 (https=)
RU2011108026A (ru) Комбинированная терапия туберкулеза
RU2015120216A (ru) Ингибиторы тирозинкиназы брутона
JP2014523851A5 (https=)
JP2015509103A (ja) イミダゾピロリジノン化合物
HRP20171028T1 (hr) Indolski i indazolski spojevi koji aktiviraju ampk
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов
RU2015123499A (ru) Соединения замещенной триазолбороновой кислоты
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
RU2018114077A (ru) Биарильное производное и содержащее его лекарственное средство
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
BR112014011981A2 (pt) formulações farmacêuticas
JP2019501879A5 (https=)
JP2016540045A5 (https=)